Cargando…

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine

Oliceridine is a G protein–biased ligand at the μ‐opioid receptor in development for treatment of moderate to severe acute pain. A phase 1, open‐label, single‐dose study investigated the pharmacokinetics and safety of oliceridine 0.5 mg intravenous (IV) in subjects with end‐stage renal disease (ESRD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nafziger, Anne N., Arscott, Kelly A., Cochrane, Kristina, Skobieranda, Franck, Burt, David A., Fossler, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383509/ https://www.ncbi.nlm.nih.gov/pubmed/31697049 http://dx.doi.org/10.1002/cpdd.750

Ejemplares similares

A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty
por: Singla, Neil, et al.
Publicado: (2017)

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine
por: Fukumura, Kazuya, et al.
Publicado: (2019)

APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy
por: Viscusi, Eugene R, et al.
Publicado: (2019)

Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials
por: Hammer, Gregory B., et al.
Publicado: (2021)

APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty
por: Singla, Neil K., et al.
Publicado: (2019)

Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain
por: Ayad, Sabry, et al.
Publicado: (2020)

Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis
por: Bergese, Sergio, et al.
Publicado: (2020)

A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects
por: Fossler, Michael J., et al.
Publicado: (2020)

Oliceridine- Opioid of the 21(st) Century
por: Goudra, Basavana
Publicado: (2022)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Dayal, Satish, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
por: Bækdal, Tine A., et al.
Publicado: (2018)

A Dive Into Oliceridine and Its Novel Mechanism of Action
por: Shah, Anjali, et al.
Publicado: (2021)

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment
por: Mercier, Anne-Kristina, et al.
Publicado: (2023)

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
por: Granhall, Charlotte, et al.
Publicado: (2018)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Oliceridine and its potential to revolutionize GI endoscopy sedation
por: Goudra, Basavana, et al.
Publicado: (2020)

Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials
por: Beard, Timothy L., et al.
Publicado: (2020)

Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986
por: Trivedi, Ashit, et al.
Publicado: (2022)

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
por: Borin, Marie T, et al.
Publicado: (2019)

Functional bias of morphine and oliceridine under conditions of minor injury
por: Nwaneshiudu, Chinwe, et al.
Publicado: (2021)

Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
por: Jensen, Lene, et al.
Publicado: (2018)

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016)

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
por: Preston, Richard A., et al.
Publicado: (2020)

Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults
por: Lambert, David, et al.
Publicado: (2020)

Pharmacological Advances in Opioid Therapy: A Review of the Role of Oliceridine in Pain Management
por: Kaye, Alan D., et al.
Publicado: (2021)

Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review
por: Daksla, Neil, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects
por: O’Donnell, John, et al.
Publicado: (2019)

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
por: Srinivas, Nithya, et al.
Publicado: (2020)

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment
por: Topletz-Erickson, Ariel R., et al.
Publicado: (2022)

Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment
por: Smolders, Elise J., et al.
Publicado: (2016)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
por: Akce, Mehmet, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment
por: Agersnap, Mikkel Askjær, et al.
Publicado: (2023)

ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The µ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy
por: Bergese, Sergio D, et al.
Publicado: (2019)

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
por: Badros, A Z, et al.
Publicado: (2013)

Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
por: Berg, Jolene K., et al.
Publicado: (2018)

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
por: Huguet, Jade, et al.
Publicado: (2021)

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies
por: Tomkinson, Helen, et al.
Publicado: (2011)

Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment
por: Agersnap, Mikkel Askjær, et al.
Publicado: (2023)

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
por: Fontes, Magda S. C., et al.
Publicado: (2022)

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
por: Kunz, Christina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3708jndf6imaesn3m0lndabr44